Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study | Zendy

Thomas Rappl | Zendy; Parvizi | Zendy; Wiedner | Zendy; May | Zendy; Kranzelbinder | Zendy; Herwig Friedl | Zendy; Paul Wurzer | Zendy

Open Access

Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study

Author(s) -

Thomas Rappl,

Parvizi,

Wiedner,

May,

Kranzelbinder,

Herwig Friedl,

Paul Wurzer

Publication year - 2013

Publication title -

clinical cosmetic and investigational dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.73

H-Index - 35

ISSN - 1178-7015

DOI - 10.2147/ccid.s41537

Subject(s) - double blind , medicine , pathology , placebo , alternative medicine

Three botulinum neurotoxin type A preparations (incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA) are widely approved in Europe and in the US for the treatment of glabellar frown lines. The purpose of this study was to determine and compare the time to onset and duration of treatment effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA for the treatment of glabellar frown lines.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research